Trial Profile
Phase II Trial of Fulvestrant and Bevacizumab in Patients With Metastatic Breast Cancer Previously Treated With an Aromatase Inhibitor.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Bevacizumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Apr 2018 Status changed from active, no longer recruiting to completed.
- 10 Jul 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 18 Jun 2012 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.